Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Teva’s finance chief Mike McClellan is leaving the company in November. But he maintains his departure is solely due to personal reasons.
Endo has named a head for its sterile injectables and generics operations; Hikma has appointed an R&D head; Acino has a new leader for its Latin American business; Alvogen has appointed a general counsel; and Julphar has shaken up its senior management team.
Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.
Neuraxpharm has appointed Craig Bowen as general manager of its UK affiliate at the same time as the European central nervous system specialist has launched its first products in the UK market.
Stada has turned to the FMCG world to find a head for its German operations, while former FDA commissioner Scott Gottlieb has linked up with Pfizer, and Nippon Kayaku has a new pharma head.
Apurva Saraf heads up corporate development for Amneal, Salvatore Butti becomes Stada’s general manager in Italy and Vectura searches for a new CEO.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.